Search results
Analysts Just Made A Substantial Upgrade To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts
Simply Wall St. via Yahoo Finance· 1 year agoAxsome Therapeutics, Inc. (NASDAQ:AXSM) shareholders will have a reason to smile today, with the...
Axsome Tumbles On An Unexpected Setback For Its Alzheimer's Drug
Investor's Business Daily· 3 months agoAxsome Therapeutics reported strong fourth-quarter sales Tuesday, but AXSM stock tumbled on a...
Analysts Are Updating Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Estimates After Its...
Simply Wall St. via Yahoo Finance· 2 years agoShareholders of Axsome Therapeutics, Inc. (NASDAQ:AXSM) will be pleased this week, given that the...
Highly Rated Axsome Surges On Earnings Beat. And Here's Why BioXcel Reversed.
Investor's Business Daily· 1 year agoAxsome Therapeutics and BioXcel Therapeutics issued divergent earnings reports Monday. BTAI stock...
Axsome Therapeutics Expects Up To $11.5 Billion In Peak Sales, Wallops Analysts' Forecasts
Investor's Business Daily· 12 months agoAxsome Therapeutics expects its eight products to generate up to $11.5 billion in peak U.S. sales,...
What Is The Ownership Structure Like For Axsome Therapeutics, Inc. (NASDAQ:AXSM)?
Simply Wall St. via Yahoo Finance· 2 years agoThe big shareholder groups in Axsome Therapeutics, Inc. (NASDAQ:AXSM) have power over the company....
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Earnings Haven't Escaped The Attention Of Investors
Simply Wall St. via Yahoo Finance· 9 months agoAxsome Therapeutics, Inc.'s (NASDAQ:AXSM) price-to-sales (or "P/S") ratio of 19.3x may look like a...
Institutional investors in Axsome Therapeutics, Inc. (NASDAQ:AXSM) see US$220m decrease in market...
Simply Wall St. via Yahoo Finance· 1 year agoTo get a sense of who is truly in control of Axsome Therapeutics, Inc. (NASDAQ:AXSM), it is...
Investors bid Axsome Therapeutics (NASDAQ:AXSM) up US$448m despite increasing losses YoY, taking...
Simply Wall St. via Yahoo Finance· 2 years agoLong term investing can be life changing when you buy and hold the truly great businesses. And we've...
1 Risky Growth Stock Wall Street Says Is Poised for a 47% Rally
Motley Fool· 1 year agoAn average of Wall Street analyst forecasts suggests share prices of Axsome Therapeutics (NASDAQ:...